Where Does Ripretinib Fit Into Treatment for GIST? : vimarsa

The relative newcomer to the field, ripretinib, was compared to standard second-line treatment with sunitinib in patients with advanced gastrointestinal stromal tumors.

Related Keywords

Germany , New York , United States , Columbia University , West German , Sebastian Bauer , Gary Schwartz , Daiichi Sankyo , Nanobiotix Incyte , Glaxosmithkline , Schwartz , Drug Administration , Boehringer Ingelheim , Deciphera Pharmaceuticals , Novartis , German Cancer Centre , Pfizer , Clinical Oncology , West German Cancer Centre , Blueprint Medicines , Adcendo Aps , Gist , Gastrointestinal Stromal Tumor , Umor Gastrointestinal Stromal , Antineoplastic Drug , Nti Cancer Agents , Evacizumab , Rlotinib , Efitinib , Matinib , Ituximab , U11248 , Unitinib , Rastuzumab , Biologic Therapy , Antibody Drug Conjugates Adcs , Clinical Research , Clinical Trials , Linical Studies , Healthcare And Medical Technology , Ealth And Medical Tech , Ealth And Med Tech , Ealth And Medica ,